NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine
- Wednesday, November 17, 2021, 7:00
- Finance
- Add a comment
NEW HAVEN, Conn., Nov. 17, 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven”) announced today that NURTEC® ODT (rimegepant) was approved by the Kuwait Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC…
About the Author
adminasapcorp has written 41735 stories on this site.